专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

11. 发明申请

US20130085127A1 HETEROCYCLIC COMPOUND AND H1 RECEPTOR ANTAGONIST 有权
标题翻译：杂环化合物和H1受体拮抗剂
公开(公告)号：US20130085127A1
公开(公告)日：2013-04-04
申请号：US13699892
申请日：2011-05-23
申请人： Makoto Okada , Koichi Hasumi , Takahiro Nishimoto , Miwa Yoshida , Kouki Ishitani , Tomoji Aotsuka , Hashime Kanazawa
发明人： Makoto Okada , Koichi Hasumi , Takahiro Nishimoto , Miwa Yoshida , Kouki Ishitani , Tomoji Aotsuka , Hashime Kanazawa
IPC分类号： C07D405/06 , C07D401/06 , C07D211/46
CPC分类号： C07D405/06 , C07D211/46 , C07D213/79 , C07D333/40 , C07D401/06 , C07D407/08 , C07D409/06 , C07D413/06 , C07D417/06
摘要： A heterocyclic compound useful as an antiallergic agent is provided.A compound represented by the following formula (1) or a salt thereof: wherein the ring A is a homocyclic or heterocyclic ring; the ring B is a heterocyclic ring which contains G and nitrogen atom N as constituent atoms thereof, wherein G is CH or N; R1 is a carbonyl group or an alkylene group; R2a and R2b are an alkyl group, a cycloalkyl group, an aryl group, or a heterocyclic group; X is an oxygen atom or a sulfur atom; Z is a hydroxyl group, an alkoxy group, a cycloalkyloxy group, an aryloxy group, an aralkyloxy group, an amino group, or an N-substituted amino group; and n is 0 or 1; with the proviso that when the ring A is a benzene ring or when the ring B is a piperazine ring, R1 is an alkylene group which may have a substituent.
摘要翻译：提供了可用作抗过敏剂的杂环化合物。由下式（1）表示的化合物或其盐：其中环A是稠环或杂环; 环B是含有G和氮原子N作为其构成原子的杂环，其中G是CH或N; R1是羰基或亚烷基; R2a和R2b是烷基，环烷基，芳基或杂环基; X是氧原子或硫原子; Z是羟基，烷氧基，环烷氧基，芳氧基，芳烷氧基，氨基或N-取代氨基; 并且n为0或1; 条件是当环A为苯环时，或当环B为哌嗪环时，R 1为可具有取代基的亚烷基。

12. 发明申请

US20090318496A1 PREPARATION CONTAINING FIBRATE AGENT AND PROCESS FOR PRODUCING THE SAME 审中-公开
标题翻译：含有纤维素试剂的制剂及其生产方法
公开(公告)号：US20090318496A1
公开(公告)日：2009-12-24
申请号：US12309822
申请日：2006-08-04
申请人： Hashime Kanazawa , Masaya Morimoto , Naoto Tanimori
发明人： Hashime Kanazawa , Masaya Morimoto , Naoto Tanimori
IPC分类号： A61K31/47 , A61K31/216
CPC分类号： A61K31/216 , A61K31/47
摘要： A preparation (pharmaceutical composition) reducing a concentration of a free fatty acid and/or fibrinogen in the blood is prepared. The preparation contains a statin agent comprising at least a statin compound having a benzopyridine skeleton (e.g., pitavastatin) and a fibrate agent (e.g., fenofibrate). The preparation is useful as a preventive or treating agent for hyper-free fatty acidemia, metabolic syndrome, or type II diabetes.
摘要翻译：制备减少血液中游离脂肪酸和/或纤维蛋白原浓度的制剂（药物组合物）。该制剂含有至少包含具有苯并吡啶骨架的他汀类化合物（例如匹伐他汀）和贝特类药物（例如非诺贝特）的他汀类药物。该制剂可用作高游离脂肪酸血症，代谢综合征或II型糖尿病的预防或治疗剂。

13. 发明申请

US20070197602A1 Combined pharmaceutical composition 审中-公开
标题翻译：组合药物组合物
公开(公告)号：US20070197602A1
公开(公告)日：2007-08-23
申请号：US10588725
申请日：2005-02-08
申请人： Hashime Kanazawa , Kouki Ishitani , Katsuichi Sudo , Naoto Tanimori
发明人： Hashime Kanazawa , Kouki Ishitani , Katsuichi Sudo , Naoto Tanimori
IPC分类号： A61K31/44 , A61K31/19 , A61K31/21 , A61K31/35
CPC分类号： A61K45/06 , A61K31/192 , A61K31/194 , A61K31/216 , A61K31/22 , A61K31/366 , A61K31/40 , A61K31/405 , A61K31/4418 , A61K31/445 , A61K31/47 , A61K31/7008 , A61K31/7028 , A61K2300/00
摘要： At least one hyperlipidemic agent selected from the group consisting of a fibrate compound (e.g., fenofibrate, bezafibrate, or a salt thereof) and an HMG-CoA reductase inhibitor (e.g., a statin compound, for example, pravastatin, atorvastatin, or salts thereof) is, as active ingredients, combined with an α-glucosidase inhibitor (e.g., voglibose, and acarbose) in the pharmaceutical composition of the present invention. The proportion of the α-glucosidase inhibitor may be about 0.001 to 50 parts by weight relative to 100 parts by weight of the hyperlipidemic agent. The present invention provides a pharmaceutical composition which is excellent in prophylactic and/or therapeutic effect on metabolic syndrome, hyperlipemia, diabetes, diabetes complications, etc, and has few side effects.
摘要翻译：至少一种选自贝特类化合物（例如非诺贝特，苯扎贝特或其盐）和HMG-CoA还原酶抑制剂（例如他汀类化合物，例如普伐他汀，阿托伐他汀或其盐的高脂血症药物）作为活性成分与本发明的药物组合物中的α-葡糖苷酶抑制剂（例如伏格列酮和阿卡波糖）组合。相对于100重量份的高脂血症药，α-葡糖苷酶抑制剂的比例可以为约0.001至50重量份。本发明提供了对代谢综合征，高脂血症，糖尿病，糖尿病并发症等的预防和/或治疗效果优异的副作用少的药物组合物。

14. 发明申请

US20060040972A1 Pyrazolonaphthyridine derivative 有权
标题翻译：吡唑并萘啶衍生物
公开(公告)号：US20060040972A1
公开(公告)日：2006-02-23
申请号：US10533806
申请日：2003-11-05
申请人： Hashime Kanazawa , Tomoji Aotsuka , Kentarou Kumazawa , Kouki Ishitani , Takashi Nose
发明人： Hashime Kanazawa , Tomoji Aotsuka , Kentarou Kumazawa , Kouki Ishitani , Takashi Nose
IPC分类号： A61K31/4745 , C07D471/14
CPC分类号： A61K31/4375 , A61K31/444 , C07D471/14
摘要： The target is to provide PDE IV inhibitors which have a highly potent anti-asthmatic and/or COPD-prophylactic/therapeutic profile with unexpectedly excellent safety. A compound of the formula (1): wherein A is phenyl, pyridyl, 1-oxypyridyl, or thienyl, which may be unsubstituted or optionally substituted with one or more members selected from the group consisting of hydroxyl, halogen, cyano, nitro, lower alkyl, lower alkoxy, lower alkylcarbonyloxy, amino, carboxyl, lower alkoxycarbonyl, carboxy-lower alkylene, lower alkoxycarbonyl-lower alkylene, lower alkylsulfonyl, lower alkylsulfonylamino, and ureido; R1 is a group selected from the group consisting of hydrogen, hydroxyl, halogen, cyano, nitro, lower alkoxy, amino, carboxyl, and lower alkoxycarbonyl; R2 is hydrogen or lower alkyl; and m is an integer of 1 to 3; or a pharmaceutically acceptable salt thereof, possesses highly excellent PDE IV-specific inhibitory actions and is useful as an anti-asthmatic drug and/or a prophylactic/therapeutic drug for COPD with high safety.
摘要翻译：目标是提供具有非常有效的抗哮喘和/或COPD预防/治疗特征的PDE IV抑制剂，具有出人意料的极好的安全性。式（1）的化合物：其中A是苯基，吡啶基，1-氧代吡啶基或噻吩基，其可以是未取代的或任选地被一个或多个选自羟基，卤素，氰基，硝基，低级烷基，低级烷氧基，低级烷基羰基氧基，氨基，羧基，低级烷氧基羰基，羧基 - 低级亚烷基，低级烷氧基羰基 - 低级亚烷基，低级烷基磺酰基，低级烷基磺酰基氨基和脲基。 R 1是选自氢，羟基，卤素，氰基，硝基，低级烷氧基，氨基，羧基和低级烷氧基羰基的基团。 R 2是氢或低级烷基; m为1〜3的整数。或其药学上可接受的盐具有非常优异的PDE IV特异性抑制作用，并且可用作具有高度安全性的抗哮喘药和/或用于COPD的预防/治疗药物。

15. 发明授权

US09365553B2 Heterocyclic compound and H1 receptor antagonist 有权
标题翻译：杂环化合物和H1受体拮抗剂
公开(公告)号：US09365553B2
公开(公告)日：2016-06-14
申请号：US13699892
申请日：2011-05-23
申请人： Makoto Okada , Koichi Hasumi , Takahiro Nishimoto , Miwa Yoshida , Kouki Ishitani , Tomoji Aotsuka , Hashime Kanazawa
发明人： Makoto Okada , Koichi Hasumi , Takahiro Nishimoto , Miwa Yoshida , Kouki Ishitani , Tomoji Aotsuka , Hashime Kanazawa
IPC分类号： C07D401/06 , C07D211/46 , C07D405/06 , C07D213/79 , C07D333/40 , C07D407/08 , C07D409/06 , C07D413/06 , C07D417/06
CPC分类号： C07D405/06 , C07D211/46 , C07D213/79 , C07D333/40 , C07D401/06 , C07D407/08 , C07D409/06 , C07D413/06 , C07D417/06
摘要： A heterocyclic compound useful as an antiallergic agent is provided.A compound represented by the following formula (1) or a salt thereof: wherein the ring A is a homocyclic or heterocyclic ring; the ring B is a heterocyclic ring which contains G and nitrogen atom N as constituent atoms thereof, wherein G is CH or N; R1 is a carbonyl group or an alkylene group; R2a and R2b are an alkyl group, a cycloalkyl group, an aryl group, or a heterocyclic group; X is an oxygen atom or a sulfur atom; Z is a hydroxyl group, an alkoxy group, a cycloalkyloxy group, an aryloxy group, an aralkyloxy group, an amino group, or an N-substituted amino group; and n is 0 or 1; with the proviso that when the ring A is a benzene ring or when the ring B is a piperazine ring, R1 is an alkylene group which may have a substituent.
摘要翻译：提供了可用作抗过敏剂的杂环化合物。由下式（1）表示的化合物或其盐：其中环A是稠环或杂环; 环B是含有G和氮原子N作为其构成原子的杂环，其中G是CH或N; R1是羰基或亚烷基; R2a和R2b是烷基，环烷基，芳基或杂环基; X是氧原子或硫原子; Z是羟基，烷氧基，环烷氧基，芳氧基，芳烷氧基，氨基或N-取代氨基; 并且n为0或1; 条件是当环A为苯环时，或当环B为哌嗪环时，R 1为可具有取代基的亚烷基。

16. 发明授权

US08119686B2 Spiroquinone compound and pharmaceutical composition 失效
标题翻译：螺醌化合物和药物组合物
公开(公告)号：US08119686B2
公开(公告)日：2012-02-21
申请号：US12312640
申请日：2007-11-21
申请人： Shinji Yokoyama , Hashime Kanazawa , Tomoji Aotsuka
发明人： Shinji Yokoyama , Hashime Kanazawa , Tomoji Aotsuka
IPC分类号： A61K31/385 , C07D339/02
CPC分类号： C07D339/06
摘要： A novel spiroquinone derivative having a high ABCA1 stabilization effect and being useful for prophylactic and/or therapeutic agents for various diseases developing hypo-high density lipoproteinemia is obtained. The novel spiroquinone derivative is a compound represented by the following formula: wherein R1a, R1b, R1c and R1d each represents a hydrogen atom, a halogen atom, an alkyl group which may have a substituent, or an alkoxy group which may have a substituent, and R2a and R2b each represents a hydrogen atom, or an alkyl group which may have a substituent (e.g., a carboxyl group, an alkoxycarbonyl group, a carbamoyl group, and an N-substituted carbamoyl group), the groups R2a and R2b may bond together to form a hydrocarbon ring with an adjacent carbon atom, provided that compounds in which all of the groups R1a, R1b, R1c and R1d are t-butyl groups, and both of the groups R2a and R2b are hydrogen atoms or both of the groups R2a and R2b are methyl groups are excluded; or a pharmacologically acceptable salt thereof.
摘要翻译：获得具有高ABCA1稳定作用并可用于发生低密度脂蛋白血症的各种疾病的预防和/或治疗剂的新型螺醌衍生物。新型螺醌衍生物为下式表示的化合物：其中R1a，R1b，R1c和R1d各自表示氢原子，卤素原子，可具有取代基的烷基或可具有取代基的烷氧基， R2a和R2b各自表示氢原子或可具有取代基的烷基（例如羧基，烷氧基羰基，氨基甲酰基和N-取代氨基甲酰基），基团R 2a和R 2b可以键合一起形成具有相邻碳原子的烃环，条件是其中所有基团R 1a，R 1b，R 1c和R 1d都是叔丁基，并且基团R 2a和R 2b各自为氢原子或两个基团 R2a和R2b是甲基; 或其药理学上可接受的盐。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式